Trial shows antiplatelet therapy needs personalization after stent implantation
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had…
Author: Team Health Accessible
Milvexian fails to reduce cardiovascular events after acute coronary syndrome
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was…
Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous…
Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart…
Atorvastatin reduces major cardiovascular events but misses disability-free survival goal
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not…
REACT study maps widespread silent atherosclerosis across adult lifespan
Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the…
Immediate evolocumab use after heart attack improves cholesterol goals but not survival
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction…
Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic…
New study detects silent atherosclerosis in healthy young adults
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear. An international study led by Professor…
New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had…